Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...
manilatimes4d
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 ...
Buy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward Scenario
Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig ...
devdiscourse5d
Novo Nordisk's Obesity Drug Quest: High Stakes and New Challenges
Novo Nordisk's experimental obesity drug CagriSema shows similar side effects to its GLP-1 drugs, with potential for 25% ...
Novo Nordisk affirms 25% weight-loss expectation for experimental drug CagriSema
Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...
Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
Bagsværd, 6 November 2024 - Financial report for the period 1 January 2024 to 30 September 2024 Operating profit increased by ...
thecardiologyadvisor.com5d
Promising Obesity Pharmacotherapies on the Horizon
Monlunabant was evaluated in a phase 2a trial (ClinicalTrials.gov Identifier: NCT05891834) in patients with obesity and metabolic syndrome (N=243). Results showed patients treated with monlunabant ...
Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024
Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.
Business Insider6d
Corbus Pharmaceuticals’ CRB-913: A Promising and Safer Alternative in Obesity Treatment with a Buy Rating
The compound’s distinctive pharmacokinetic profile, with significantly lower brain exposure compared to monlunabant, suggests a promising safety profile which could reshape perceptions about CB1 ...
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...